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Though traditionally regarded as immunosuppressive, radiotherapy may also stimulate 
immune cells and facilitate an anti-tumor immune response. We therefore aimed to explore 
the prognostic significance of immune cell markers in non-small cell lung cancer (NSCLC) 
patients treated with postoperative radiotherapy (PORT). 
 
Methods 
In addition to demographic and clinicopathological information, tumor tissue samples were 
collected and tissue microarrays (TMAs) were constructed from 55 patients with stage I-IIIA 
NSCLC who received PORT. Tumor and stromal expression of CD1a+, CD3+, CD4+, CD8+, 
CD20+, CD56+, CD68+, CD117+ and CD138+ cells, as well as M-CSF and CSF-1R, was 
assessed by immunohistochemistry. 
 
Results 
In univariate analysis, high co-expression of CD4+ and CD8+ T lymphocytes as well as high 
expression of CD1a+ dendritic cells in the tumor stroma correlated with improved disease-
specific survival (DSS). In multivariate analysis patients with stromal ↓CD4/↓CD8 expression 




Stromal ↓CD4/↓CD8 expression was an independent negative prognostic factor for survival in 






Lung cancer remains the leading cause of cancer-related mortality in the western world, and is 
projected to account for 28% of all cancer deaths in the United States in 2012 [1]. Non-small 
cell lung cancer (NSCLC) represents 80–85% of all lung cancers, and surgical resection of 
early stage disease presents the best opportunity for long term survival [2]. Despite extensive 
research efforts, the prognosis of NSCLC patients, even with complete surgical resection, 
remains disappointing [3]. Immunotherapy has shown potential impact in the treatment 
NSCLC, and clinical studies on the significance of immunological markers are warranted [4]. 
 
The immune system can be divided into two compartments, the innate and the adaptive 
immune systems. The innate system consists of dendritic cells (DCs), natural killer (NK) 
cells, NK T cells, macrophages, neutrophils, basophils and eosinophils, and is the body's first 
line of defense against pathogens. B cells, CD4+ T helper cells and CD8+ cytotoxic T cells, 
express a diverse set of somatically generated antigen-specific receptors, thereby enabling the 
highly specific adaptive immune response [5]. 
 
Tumor-promoting inflammation mediated by cells of the innate immune system is recognized 
as an enabling characteristic of cancer development, and the tumor's ability of avoiding 
immune destruction is recognized as an emerging hallmark of cancer [6]. Innate cells such as 
macrophages, mast cells and neutrophils contribute to tumor angiogenesis, and tumor 
infiltration by such cells often correlates with a poor prognosis [6] and [7]. In contrast, an 




While cell death by damage to tumor DNA is thought to be the main mode of action of 
radiotherapy, evidence suggests that, it in addition mobilizes tumor specific immunity and 
stimulates an anti-tumor response [8] and [9]. Hence, radiotherapy can improve the effect of 
immunotherapy in cancer treatment [10]. Recent studies have also shown that the efficacy of 
high dose radiotherapy depends on the presence of CD8+ T cells [11] and [12]. We previously 
reported on the prognostic impact of both innate and adaptive immune cell markers in 
NSCLC [13], [14] and [15]. In addition, we have shown that angiogenic markers have 
prognostic impact in surgically resected NSCLC patients receiving postoperative radiotherapy 
(PORT) [16]. To the best of our knowledge, no studies have explored the prognostic 
significance of immune cell markers in this group of patients. In light of the link between 
radiotherapy and tumor specific immune responses, we aimed to explore if in situ immunity 
had an impact on survival in NSCLC patients treated with PORT. 
 
Materials and methods 
 
Patients 
Patients surgically resected for NSCLC stage I-IIIA at the University Hospital of Northern 
Norway and Nordland Central Hospital from 1990 through 2004 were identified in this 
retrospective study. In total, 371 patients from the hospital databases were registered. Of 
these, sixty-three patients received radiotherapy within 12 weeks postoperatively, with a 
cumulative radiation dose of ≥50 Gy. Eight patients were excluded due to: Preoperative 
chemotherapy (n = 3), other malignancy within 5 years prior to NSCLC diagnosis (n = 3) or 
inadequate paraffin-embedded surgical specimens (n = 2). A total of 55 patients were thereby 
included in the study. Adjuvant chemotherapy had not been introduced in Norway during this 
period (1990–2004). Clinicopathologic and demographic data were collected retrospectively. 
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This study includes follow up data as of January 2011. Patients were staged according to the 
revised 7th edition of UICC TNM classification of lung cancer [17], and histologically graded 
and subtyped according to the World Health Organization guidelines [18]. The Norwegian 
Data Inspectorate and The Regional Committee for Medical and Health Research Ethics 
approved the study. 
 
Microarray construction 
All specimens were examined by two pathologists (S.Al-S and K.Al-S). The most 
representative paraffin blocks were selected and two areas of viable tumor cells (neoplastic 
epithelium) and two from the central tumor-surrounding stroma were chosen and marked on 
the donor blocks. The tissue microarrays were assembled using a tissue-arraying instrument 
(Beecher Instruments, Silver Springs, MD, USA). The detailed methodology has been 
reported previously [19]. Using a 0.6 mm-diameter stylet, cores from two separate predefined 
neoplastic epithelial areas and two stromal areas were transferred to recipient blocks. To 
include all core samples, a total of eight tissue array blocks were constructed. Multiple 4-μm 
sections were cut with a Micron microtome (HM355S) and stained with specific antibodies 
for immunohistochemical analysis. Both normal lung tissues localized distant to the primary 
tumor and one slide with normal lung tissue sample from 20 patients without a diagnosis of 
cancer were used as controls. 
 
Immunohistochemistry 
The following antibodies from Ventana Medical (Tucson, Ariz, USA) were used in this study: 
CD20 (clone L26), CD8 (clone 1A5), CD68 (clone KP1), CD138 (clone B-A38), CD1a, CD3 
(clone PS1), CD117 (clone anti-C Kit, 9.7) and CD138 (clone B-A38). All Ventana antibodies 
were prediluted from the manufacturer. In addition CD4 (clone 1F6, Novocastra Laboratories 
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Ltd. Newcastle upon Tyne, UK, dilution 1:5), M-CSF (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA, dilution 1:5) and CSF-1R (clone H-300, Santa Cruz Biotechnology, dilution 
1:25) were used. The detailed immunohistochemical procedures have been published 
previously [13], [14] and [15]. For each antibody, including negative staining controls, all 
staining was done in a single experiment. As negative staining controls, the primary 
antibodies were replaced with the primary antibody diluents. 
 
Scoring of Immunohistochemistry 
Tissue sections were scored by light microscopy for degree of infiltration of the specified 
immune cells. 
 
The CD8+ cells were scored as low if ≤5% or as high if >5% of the whole surface area of the 
epithelial compartments were infiltrated, and was scored as low if ≤50% or high if >50% of 
the total nucleated surface area of the stromal compartments were infiltrated. CD4+ cells were 
scored as high if representing ≥5% or ≥25% of the total nucleated cells in the epithelial and 
stromal compartments, respectively. Few CD4+ and CD8+ T cells (0 to <5% of the total 
nucleated cells) were observed in the interstitial tissue of the nonneoplastic controls. 
 
CD1a+ cells were scored as low if absent or if representing <1% of the nucleated cells and 
high otherwise, in both epithelial and stromal compartments. Intraepithelial CD68+ cells were 
scored as low if absent or representing <1% of the nucleated cells and high otherwise, while 
the more abundant stromal CD68+ cells were scored as low if they represented <25% of the 
total nucleated cells and high otherwise. CD56+ cells were scored as present (high score) or 
absent (low score) in both epithelial and stromal compartments. The intensity of M-CSF and 
CSF-1R in both epithelial and stromal compartments were scored as follows: 0 = negative; 1 
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= weak; 2 = intermediate and 3 = strong. The cell density of the stroma was scored as the ratio 
of positive cells compared to the surface area of the extracellular matrix in the following 
manner: 1 = low density (<25% cell/matrix ratio); 2 = intermediate density (25–50%) and 3 = 
high density (>50%). High expression in the tumor epithelium was defined as a score ≥1.5 for 
both M-CSF and CSF-1R. Expression in the stroma was calculated by adding density score to 
intensity score prior to categorizing into low and high expression. High expression was 
defined as >3.5 for M-CSF and >3 for CSF-1R. 
 
CD3+ cells were scored as low if they represented <1% of the nucleated cells in the epithelial 
cores and high otherwise, and as high if representing >50% of nucleated cells in the stroma 
and low otherwise. CD138+ cells were scored as high if representing >5% of the nucleated 
cells in the epithelial compartment or >25% in the stromal compartment, and as low 
otherwise. As CDD138+ cells also stain epithelial cells themselves the staining intensity in 
the epithelial compartment was scored in the following manner: 0 = negative; 1 = weak; 2 = 
intermediate and 3 = strong. High expression was defined as a score >1. CD117+ cells were 
extremely rare in the epithelial compartments and sparse in the stromal compartment, they 
were therefore scored as present (high score) or absent (low score) and only in the stromal 
compartment. 
 
All samples were anonymized and independently scored by two pathologists (S.A.S and 
K.A.S). In case of disagreement, the slides were re-examined and the observers reached a 
consensus. When assessing one marker in a given core, both observers were blinded to the 
scores of the other markers as well as to the patient's outcome. The interobserver scoring 
agreement between the two pathologists was tested on the current material previously [20], 





All statistical analyses were carried out using the statistical package IBM SPSS, version 20 
(SPSS Inc., Chicago, IL, USA). Univariate analysis of the association between marker 
expression and survival was done using the Kaplan–Meier method and the statistical 
significance of differences between survival curves was assessed by the log-rank test. The 
disease-specific survival (DSS) was determined from the date of surgery to the time of lung 
cancer death. Only variables of significant value from the univariate analysis were entered 
into the multivariate analysis, using the Cox proportional hazards model. Probability for 




















Demographic, clinical and histopathology variable are presented in Table 1.  The median 
survival time for all 55 patients was 24 months (range 3-197). The 5-year DSS was 44% and 
the 10-year DSS was 42%.  Median patient age was 65 years (range 39-76) and the majority 
of patients were men (69%). The NSCLC tumors were comprised of 33 squamous cell 
carcinomas, 16 adenocarcinomas and 6 large cell carcinomas.  
 
In univariate analysis, weight loss >10% (P = 0.029), histology (p=0.048), poor tumor cell 
differentiation (p=0.026) and nodal metastasis (P = 0.010) were prognostic variables (Table 
1). The association between molecular marker expression and disease-specific survival data is 
presented in Table 2. The co-expression of CD4 and CD8 was a strong significant prognostic 
factor in this group of patients receiving PORT (Fig. 1 and Table 2), as was stromal CD4 
expression (Table 2). In addition, patients with high stromal expression of CD1a had a 
significantly better DSS than those with a low expression (Fig. 2).     
 
Multivariate analysis 
None of the clinicopathologic variables emerged significant in multivariate analysis, while the 
hazard ratio was 21.2 (CI95% 4.5 - 120.4, P < 0.001) for the ↓CD4/↓CD8 combination and 
1.8 (CI95% 0.4-8.4, P = 0.430) for other CD4/CD8 combinations, when compared to the 
reference group ↑CD4/↑CD8 (Table 3). Low CD1a had a hazard ration of 2.5 (CI95% 0.97 – 








Fig.1. Disease-specific survival curves according to the co-expression of stromal CD4 and CD8 in 54 NSCLC 




Fig. 2. Disease-specific survival curves according to the expression of stromal CD1a in 53 NSCLC patients 




We present the first study examining the prognostic impact of immune cell marker expression 
in surgically resected NSCLC patients treated with adjuvant radiotherapy. Our main finding is 
that the stromal co-expression of CD4+ and CD8+ T lymphocytes is a strong and independent 
prognostic factor in this group. Patients with ↓CD4+/CD8+↓ expression seem to have 
remarkably poor prognosis and will therefore most likely have a very limited benefit of 
adjuvant radiotherapy. The 5-year survival rate for patients with ↑CD4+↑CD8+ expression 
(16%, n = 9) was 78%, whereas ↓CD4+↓CD8+ patients (22%, n = 12) had median survival 
rate of only 9 months, with none surviving longer than 19 months from the time of diagnosis. 
The observed hazard ratio of 21.1 between ↓CD4+↓CD8+ and ↑CD4+↑CD8+ indicates a 
substantial and independent impact on DSS. However, due to the small number of patients the 
results have to be interpreted cautiously. 
 
Hiraoka et al. have previously shown that there is a synergistic effect of simultaneous high 
CD4+ and CD8+ T-cell expression on survival in NSCLC [21], while we previously showed 
that stromal expression of CD4 and CD8 both are independent prognostic factors in NSCLC 
[13]. The high hazard ratio observed in our subgroup of patients indicates that CD4/CD8 
expression has higher prognostic significance in PORT treated patients, and may suggest a 
link between stromal in situ immunity and radiotherapy response. 
 
Results from cell lines and murine models reveal close interplay between the immune system 
and the effects of radiotherapy. Radiotherapy may enhance expression of tumor-associated 
antigens, facilitate immune-mediated targeting of the tumor stroma and diminish the activity 
of regulatory T-cells. [4]. However, our results suggest that radiotherapy alone does not up-
regulate the immune response sufficiently to inhibit tumor growth in ↓CD4/↓CD8 patients. In 
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a murine model of melanoma, Lee et al. observed that the therapeutic effect of radiotherapy 
was dependent on CD8+ T-cells, since tumors of CD8 depleted mice became radio-resistant 
[11]. Gupta et al. recently described how CD8+ T-cells are crucial for the effect of local high-
dose radiotherapy, whereas CD4+ T-cells and macrophages were not [12]. Low stromal 
CD4/CD8 may indicate an insufficient level of these cells for a successful “boosting” of the 
radiotherapy effect. Stimulating the immune response via immunotherapy could therefore 
possibly augment the responsiveness to radiotherapy in those individuals lacking concurrent 
high CD4/CD8 levels in the tumor stroma. 
 
Experimental data suggest that radiotherapy and immunotherapy may have additive and 
synergistic effects. Reits et al. showed that radiotherapy prior to adoptive treatment with 
cytotoxic T-cells greatly enhanced the efficacy of the immunotherapy [10]. Takeshima et al. 
observed that local tumor irradiation augmented the therapeutic effect of Th1 cell therapy, 
accompanied by induction of cytotoxic T-lymphocytes in the tumor draining lymph nodes and 
tumor mass [22]. In a murine model of Lewis Lung Carcinoma, Yokouchi et al. reported 
greater efficacy when combining radiotherapy with an agonistic monoclonal antibody to 
αOX40 (CD134), which augments T-cell expansion and survival, when compared to either 
single treatment given separately [23]. Similar results were presented by Gough et al., with a 
significant portion of long-term tumor-free survivors [24]. Combining CTLA-4 blockade with 
radiation, Demaria et al. were able to induce an immune-mediated inhibition of metastases in 
a mouse model of breast cancer [25]. Similarly, Dewan et al. were able to induce an abscopal 
effect by combining fractionated radiotherapy with an anti-CTLA-4 antibody [26]. Adjuvant 
immunotherapy has shown encouraging results in NSCLC [27], but few trials have looked at 
combining immunotherapy with radiotherapy. As the above presented pre-clinical studies 
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indicate, this treatment combination may be an interesting approach for resected NSCLC 
patients. 
 
Though only shown in univariate analysis, we found that a higher expression of stromal 
CD1a+ DCs confer an increased DSS when compared to low expression for patients treated 
with PORT. DCs are professional antigen presenting cells, who can process and present tumor 
associated antigens and thereby activate adaptive immune cells [28]. Radiation-induced tumor 
cell death may be associated with the production of maturation signals for DCs [29]. 
 
Teitz-Tennenbaum et al. observed that the efficacy of DC immunotherapy was enhanced by 
radiotherapy [30]. Increasing DC infiltration though immunotherapy could therefore be a 
potential strategy to improve survival in PORT treated patients. 
 
In conclusion, we have shown that low CD4/CD8 expression is an independent negative 
prognostic factor in surgically resected NSCLC treated with PORT. Though our results are 
striking, they should be considered with caution, as the number of included patients is low. 
Nevertheless, further studies are pivotal in order to elucidate the potential significance of 
CD4/CD8 expression as a predictive marker in adjuvantly irradiated NSCLC. 
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Table 1. Prognostic Clinicopathologic Variables as Predictors of Disease-Specific Survival in 55 NSCLC-Patients 










Age     0.471 
≤ 65 years 31 56 44 42  
> 65 years 24 44 41 48  
Sex     0.433 
     Female 17 31 64 53  
     Male 38 69 26 41  
Smoking       
     Never 1 2 NR 100 0.491 
     Current 31 56 41 40  
     Former  23 42 47 47  
Performance status     0.159 
     ECOG 0 28 51 47 50  
     ECOG 1  23 42 26 36  
     ECOG 2 4 7 NR 67  
Weight loss     0.029 
      10% 49 89 47 47  
      10% 6 11 8 20  
Histology      0.048 
     Squamous cell carcinoma 33 60 NR 61  
     Adenocarcinoma 16 29 21 19  
     Large Cell Carcinoma 6 11 18 17  
Differentiation      0.026 
     Poor 27 49 18 21  
     Moderate 21 38 127 65  
     Well 7 13 NR 63  
Surgical procedure     0.795 
     Lobectomy  29 53 47 43  
     Pneumonectomy 26 47 18 45  
Pathological stage     0.084 
     I 7 13 NR 83  
     II 20 36 NR 51  
     III 28 51 21 30  
Tumor status     0.923 
     1 7 13 44 40  
     2 32 58 26 44  
     3 16 29 47 45  
Nodal status     0.010 
     0 14 25 NR 75  
     1 19 35 41 50  
     2 22 40 19 21  
Surgical margins     0.174 
     Free 38 69 21 37  
     Not free 17 31 NR 60  
Vascular infiltration     0.146 
     No 42 76 64 51  
     Yes 13 24 26 21  
Clinican reason for PORT     0.063 
     Insufficient margin or tumor         
     cells in resection margin 
18 33 NR 65  
     N1 14 25.5 16 50  
     N2 20 36 19 22  
     Local recurrence 3 5.5 NR 67  
Fractioning regime     0.460 
     2,8 × 15 = 42 Gy 29 53 19 41  
     2 × 30 = 60 Gy 21 38 47 48  
     2× 25-30 = 50-60 Gy 5 9 24 40  






Table 2. Prognostic Molecular Variables as Predictors of Disease-Specific Survival in 55 NSCLC-Patients Receiving 
Adjuvant Postoperative Radiotherapy 










CD4      
Tumor     0.799 
Low 40 73 47 40  
High 14 25 44 49  
Missing 1 2    
Stroma     <0.001 
Low  12 22 9 0  
High 42 76 NR 59  
Missing 1 2    
CD8      
Tumor          0.525 
Low 41 74.5 41 45  
High 13 23.5 47 45  
Missing 1 2    
Stroma     0.072 
Low 45 82 41 39  
High 9 16 NR 78  
Missing 1 2    
CD4/CD8      
Stroma     <0.001 
↑CD4+/↑CD8+ 9 16 NR 78  
Other CD4+/CD8+ combination 33 60 127 54  
 ↓CD4+/↓CD8+ 12 22 9 0  
Missing 1 2    
Tumor     0.476 
↑CD4+/↑CD8+ 6 11 NR 63  
Other CD4+/CD8+ combination 15 27 26 31  
 ↓CD4+/↓CD8+ 33 60 47 47  
Missing 1 2    
CD20      
Tumor          0.059 
Low 40 73 26 40  
High 14 25 NR 61  
Missing 1 2    
Stroma     0.419 
Low 10 18 16 34  
High 44 80 47 47  
Missing 1 2    
CD68      
Tumor          0.661 
Low 23 42 19 45  
High 31 56 47 45  
Missing 1 2    
Stroma     0.414 
Low 38 69 47 45  
High 16 29 44 48  
Missing 1 2    
CD56      
Tumor          0.316 
Low 52 94 47 47  
High 2 4 18 0  
Missing 1 2    
Stroma     0.108 
Low 49 89 41 41  
High 5 9 NR 80  
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Missing 1 2    
CD1a      
Tumor          0.499 
Low 32 58 28 39  
High 22 40 64 54  
Missing 1 2    
Stroma     0.025 
Low 36 65 24 38  
High 17 31 NR 64  
Missing 2 4    
M-CSF      
Tumor          0.939 
Low 15 27 16 47  
High 38 69 46 44  
Missing 2 4    
Stroma     0.843 
Low 28 51 47 45  
High 24 44 41 48  
Missing 3 5    
CSF-1R      
Tumor          0.215 
Low 21 38 16 34  
High 22 40 127 55  
Missing 12 22    
Stroma     0.701 
Low 26 47 47 42  
High 27 49 41 48  
Missing 2 4    
CD3      
Tumor          0.619 
Low 38 69 41 41  
High 16 29 64 55  
Missing 1 2    
Stroma     0.212 
Low 42 76 41 41  
High 12 22 NR 57  
Missing 1 2    
CD138      
Tumor          0.292 
Low 24 43.5 19 35  
High 29 52.5 64 54  
Missing 2 4    
Stroma     0.165 
Low 24 43.5 24 33  
High 29 52.5 64 53  
Missing 2 4    
CD138 of the cancer cells      
Negative 12 22 13 25 0.058 
Positive 41 74 64 51  
Missing 2 4    
CD117 in the stroma      
Negative 36 65 47 49 0.305 
Positive 17 31 44 35  
Missing 2 4    









Table 3. Result of Cox regression analysis summarizing prognostic factors with P < 0.10 
Variable Hazard Ratio 95% Confidence Interval P 
 Stromal CD4/CD8   <0.001* 
↑CD4+/↑CD8+ 1.000   
Other CD4+/CD8+ 
combination 
1.842 (0.404-8.390) 0.430 
↓CD4+↓CD8+  21.123 (3.860-115.584) <0.001 
Stromal CD1a    
Low 2.454 (0.969-6.213) 0.058 
High 1.000   
None of the clinicopathologic variables emerged as statistically significant during Cox regression analysis 
*Overall significance as a prognostic factor 
 
